Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00346814
Status:
RECRUITING
Last Update Posted:
2009-06-30
First Post:
2006-06-29
Brief Title:
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity Structural Outcome
Sponsor:
Asociación para Evitar la Ceguera en México
Organization:
Asociación para Evitar la Ceguera en México
Study Overview
Official Title:
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity Structural Outcome
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PurposeRetinopathy of prematurity ROP continues tobe a major cause of blindness in children Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor Vascular endothelial growth factorVEGF has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None